Article

Antibiotic speeds corneal wound healing after PRK

The choice of prophylactic antibiotic after photorefractive keratectomy (PRK) is extremely important because it affects the rate of corneal epithelial wound healing.

The choice of prophylactic antibiotic after photorefractive keratectomy (PRK) is extremely important because it affects the rate of corneal epithelial wound healing.

"Healing of the corneal epithelium is central to post-PRK recovery because it is the first step to visual rehabilitation," explained Renée Solomon, MD, during the American Society of Cataract and Refractive Surgery annual meeting in Washington, DC. In a paper that she presented, gatifloxacin 0.3% (Zymar, Allergan Inc.) was shown to decrease time to complete corneal epithelial wound healing after PRK significantly compared with moxifloxacin 0.5% (Vigamox, Alcon Laboratories Inc.).

PRK for correcting refractive errors appears to be undergoing a resurgence.

Emerging bacterial resistance One of the major concerns following PRK is bacterial keratitis. Emerging bacterial resistance to the previous-generation fluoroquinolones, ciprofloxacin (Ciloxan, Alcon Laboratories) and ofloxacin (Ocuflox, Allergan), has been well documented. Prior-generation fluoroquinolones predominantly either inhibit topoisomerase II (DNA Gyrase) or topoisomerase IV and therefore only require one genetic mutation for bacteria to develop resistance. Fourth-generation fluoroquinolones are equally effective against topoisomerase II and IV, which significantly expands their spectrum of action against gram-positive agents, atypical mycobacteria, and Nocardia. This duality of action of the fourth-generation fluoroquinolones requires that for bacteria to become resistant to these agents, the bacteria must undergo two genetic mutations, resulting in a significantly decreased chance of an organism developing resistance.

These more potent fourth-generation fluoroquinolones, gatifloxacin 0.3% and moxifloxacin 0.5%, with their broader spectrum of activity and increased efficacy against gram-positive organisms, are now commonly used for infectious keratitis prophylaxis after PRK. Therefore, they are important agents to evaluate in the use of prophylaxis against post-PRK infections.

Given the significance of wound healing to the PRK procedure and the widespread use of fourth-generation fluoroquinolones, a prospective, self-controlled, double-masked, randomized study was conducted "to evaluate the effect of gatifloxacin 0.3% and moxifloxacin 0.5% on corneal epithelial wound healing after PRK," Dr. Solomon reported.

The patients were examined immediately following the procedure to confirm that there was a balance in the two groups at baseline. Then the study medications gatifloxacin 0.3% and moxifloxacin 0.5% were randomly instilled in the appropriate eyes and bandage contact lenses were applied to both eyes.

Related Videos
Arun Gulani, MD: How the Gni instrument enhances precision and control in cataract surgery
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.